NovaVision’s mission is to improve the vision of patients with neurological visual impairments and enhance the quality of life for our patients and their families; therefore we provide a portfolio of CE Marked therapy and diagnostic products for vision disorders resulting from a stroke or brain injury.
Our therapies are evidence-based, supported by decades of scientific research and clinical studies.
NovaVision’s UK subsidiary, Sight Science, was founded on the back of the successful research activities of Professor Arash Sahraie and colleagues at the University of Aberdeen. This research led to the development of the Neuro-Eye Therapy™ (NeET) program designed for the visual rehabilitation of patients who have suffered visual field loss as a result of brain injury, most often following a stroke. In 2012 Sight Science was acquired by NovaVision and Professor Sahraie became a Scientific Advisor to the NovaVision group whilst retaining his role as Professor and Chair in Vision Sciences at the University of Aberdeen.